To evaluate lotilaner treatment in patients with ocular rosacea.
Phase 2 trials begin testing efficacy in a larger patient group (100–300). This is often where biotech binary events occur — positive Phase 2 data can significantly advance a company's pipeline narrative, while failures can be terminal for a program.
Current status: ENROLLING BY INVITATION.
Tarsus Pharmaceuticals, Inc. (TARS) is the sponsoring company for this trial. BiotechSign currently grades this company C (52/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.